HilleVax's Norovirus Vaccine Shows Long-Term Immunogenicity

  • HilleVax Inc HLVX announced results from the NOR-213 Phase 2 trial of HIL-214, a virus-like particle (VLP) based vaccine for preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
  • Norovirus is a very contagious virus that causes vomiting and diarrhea.
  • NOR-213 included 528 subjects enrolled following participation in prior clinical studies of HIL-214.
  • Among all dose regimens of HIL-214, GI.1-specific, and GII.4-specific HBGA-blocking and pan-Ig responses to vaccination persisted to year 5 and, at year 5, results were similar to those previously reported at year 3. 
  • Related: SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine.
  • These results further support a single dose of HIL-214 (15/50 µg GI.1/GII.4 VLP combination with 500 µg alum) without the adjuvant as the intended regimen for future development in adults and older adults. 
  • No adverse events were deemed related to HIL-214, and no new safety risks were identified during the study.
  • Price Action: HLVX shares closed at $12.59 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!